The Royal Ottawa Mental Health Centre

Quick facts

Phase 2 pipeline

• Apo-Methylphenidate ER · Psychiatry / Neurology
  Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain by blocking their reuptake at the synapse.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• The Royal Ottawa Mental Health Centre portfolio CI brief
• The Royal Ottawa Mental Health Centre pipeline updates RSS

Related

• Sector hub: All tracked pharma companies